Epsilon M&A Deal Report - Aalto Bio
Transaction Multiples for the Valuation of Private Companies
Gallus (renamed Biosynth) / Aalto Bio
No EMAT :
114403
Announced Date :
24/05/2022
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Gallus (renamed Biosynth)
Target :
Aalto Bio
Country :
Ireland
Sector of activity :
- Health, Pharmaceuticals & Biotechnology > Biotechnology
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
Founded in 1978, Aalto Bio is a Contrat Research Organisation (CRO) providing biotechnology research services. > Develops biological materials and provides the in-vitro diagnostic (IVD) and vaccine...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|||||||
| Current |
|
|
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biotechnology » = 42
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 31
| Date | Acquirer | Target | Country | Multiples | See details |
| 21/06/2021 | Charnwood Molecular | Aurelia Bioscience | England | ** | 114304 |
| 31/03/2021 | Charles River Discovery Research Services UK | Retrogenix | England | ** | 114147 |
Source: Epsilon Research / EMAT
